EyeArt® *Autonomous AI Screening System for Diabetic Retinopathy*



Retinal Imaging

\+

EyeArt® AI



rDR Positive

vtDR Positive



EYEART PROSPECTIVE PIVOTAL CLINICAL TRIAL

942 patients, 15 centers, ETDRS gold standard

	More than mild DR	Vision-threatening DR
Sensitivity	96%	92%
Specificity	88%	94%
Imageability at primary care sites	**97%** (dilate if needed) **90%** (first attempt without dilation)	

FDA CLEARED

HEALTH CANADA APPROVED / SANTÉ CANADA APPROUVÉ

CLASS IIa MEDICAL DEVICE CE 0413

Indications for Use

The EyeArt system is indicated for use by healthcare providers to automatically detect referable diabetic retinopathy (DR) and vision-threatening DR in eyes of adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.

EyeArt has U.S. FDA 510(k) clearance, CE marking as class 2a medical device, and Health Canada license.

EYENUK

www.eyenuk.com